Crown Equity Holdings Inc. is publicly traded with the symbol CRWE. The Company primarily provides and offers advertising, branding, marketing solutions and services to boost customer awareness, as well as merchant visibility as a worldwide online multi-media publisher. For list of services offered click here

NEW YORK and CLEVELAND, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced it will host its inaugural Research and Development (R&D) Day event for the institutional investment community in New York City on Wednesday, October 11, 2017. The formal program and video webcast will begin at 9:00 am and will conclude at 1:00 pm.

“We are excited to celebrate Abeona’s first R&D day this fall and update our stakeholders on the significant progress made in our clinical stage gene therapy programs for ABO-102 and EB-101, as well as provide a review of the progress made on the IND-enabling studies for our juvenile (CLN3) and infantile (CLN1) Batten programs,” stated Timothy J. Miller, Ph.D., President and CEO. “Additionally, we plan to provide details on our manufacturing strategy for both the EB-101 program and our multiple AAV gene therapy programs,” he continued.

--Clinical progress on ABO-102 for the treatment of Sanfilippo syndrome type A, including an update on enrollment status at international clinical sites in Australia and Spain, as well as a review of the clinical data for patients currently enrolled;

--Program update on the EB-101 gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) as the Company prepares to initiate a pivotal Phase 3 clinical trial, including an update on Abeona’s manufacturing strategy, plans and progress in the development of its clinical and commercial grade production facility;

--A detailed discussion on development of Abeona’s proprietary AIM™ vector system, a next generation platform of AAV capsids being developed in collaboration with the University of North Carolina at Chapel Hill; initial studies indicate that AIM™ vectors can efficiently target multiple tissues with vector-selective tissue specificity with different routes of administration relative to first generation vectors, providing second-generation treatment approaches for patients as a redosing strategy or for patients that have neutralizing antibodies to natural AAV serotypes.

“We are pleased with the progress in our ongoing scientific collaboration with UNC on the next generation AIM™ chimeric AAV vectors, many of which have exhibited improved tissue tropisms over first generation, naturally occurring AAV serotypes, together with liver de-targeting capabilities,” stated Steven H. Rouhandeh, Executive Chairman. “We look forward to developing the AIM™ chimeric AAV vectors both internally and through strategic partnering efforts,” he continued.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development and internationalization of our clinical programs, that patients will continue to be identified, enrolled, treated and monitored in the EB-101 clinical trial, and that studies will continue to indicate that EB-101 is well-tolerated and may offer significant improvements in wound healing; the addition of two additional global clinical sites will accelerate our ability to enroll and evaluate ABO-102 as a potential treatment for patients with Sanfilippo syndrome type A, or MPS IIIA. Such statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to secure licenses for any technology that may be necessary to commercialize our products; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; our belief that initial signals of biopotency and clinical activity, which suggest that ABO-102 successfully reached target tissues throughout the body, including the central nervous system and the increased reductions in CNS GAG support our approach for intravenous delivery for subjects with Sanfilippo syndromes, and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and quarterly reports on Form 10-Q and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.